

FOR IMMEDIATE RELEASE

**Media Contacts**

Brian Kyhos  
Deborah Spak  
(224) 948-5353  
media@baxter.com

**Investor Contacts**

Mary Kay Ladone, (224) 948-3371  
Clare Trachtman, (224) 948-3085

**BAXTER ANNOUNCES BAXALTA AS THE NAME  
OF NEW GLOBAL BIOPHARMACEUTICAL COMPANY**

*Separation into two publicly traded companies remains on track for mid-2015*

DEERFIELD, Ill., Sept.10, 2014 — Baxter International Inc. (NYSE:BAX) announced today that Baxalta Incorporated will be the name of the new, publicly traded biopharmaceutical company that is expected to launch in mid-2015.

Upon completion of the separation, Baxalta plans to trade on the New York Stock Exchange (NYSE) under the symbol BXLT. Baxter International will continue trading on the NYSE under the symbol BAX. As previously announced, the corporate headquarters of both companies will be located in northern Illinois.

“The naming of Baxalta is the latest milestone on our journey to becoming a separate, independent company,” said Ludwig Hantson, Ph.D., president of Baxter BioScience, who will be chief executive officer of Baxalta. “The name Baxalta celebrates and sustains Baxter’s heritage as an innovator with a legacy of leadership by incorporating the Baxter name and coupling it with ‘alta,’ which derives from altus, Latin for ‘high’ or ‘profound.’ Both companies share a deep commitment to meeting the needs of current and future patients, which will continue to inspire us going forward.”

**BAXTER ANNOUNCES BAXALTA AS THE NAME OF NEW GLOBAL BIOPHARMACEUTICAL COMPANY – PAGE 2**

Baxalta will have approximately \$6 billion in global revenues and be a leading provider of therapeutic treatments that save, sustain and improve the lives of people with rare conditions, chronic diseases or limited treatment options. Supported by advanced technical and manufacturing expertise, Baxalta's broad pipeline is built on a legacy of innovation in bleeding disorders and immunology, and is expanding to address unmet medical needs in niche areas of oncology, as well as technology platforms such as gene therapy.

The Baxalta logo and full visual identity will be unveiled at a later date.

**About Baxter**

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

###

*This release includes forward-looking statements concerning the planned separation of Baxter's biopharmaceutical and medical products businesses. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the ability to successfully separate the businesses on the terms or timeline currently contemplated, if at all, and achieve the intended result; a material adverse change in either the biopharmaceutical or the medical products businesses; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; product quality or patient safety concerns; and other risks identified in Baxter's most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of*

**BAXTER ANNOUNCES BAXALTA AS THE NAME OF NEW GLOBAL  
BIOPHARMACEUTICAL COMPANY – PAGE 3**

*which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.*